NCT00620971 - Cisplatin/Vinorelbine/Bevacizumab Followed by Docetaxel/Gemcitabine/Bevacizumab Versus the Cisplatin/Docetaxel/Bevacizumab Combination in Locally Advanced or Metastatic NSCLC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG

Vinorelbine

Vinorelbine (oral) 60 mg/m2, on days 1 and 8 every 3 weeks for 3 cycles

DRUG

Cisplatin

Cisplatin (IV) 80 mg/m2 on day 1 every 3 weeks for 3 cycles

DRUG

Bevacizumab

Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 3 cycles

DRUG

Docetaxel

Docetaxel (IV) 75 mg/m2 on day 1 every 3 weeks for 6 cycles

DRUG

Gemcitabine

Gemcitabine(IV) 1,100 mg/m2 on day 1 and d8 every 3 weeks for 6 cycles

DRUG

Bevacizumab

Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles

DRUG

Docetaxel

Docetaxel (IV) 75 mg/m2 on day 1 every 3 weeks for 6 cycles

DRUG

Cisplatin

Cisplatin (IV) 80 mg/m2 on day 1 every 3 weeks for 6 cycles

DRUG

Bevacizumab

Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles

Trial Locations (9)

Unknown

University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupoli

"Laikon General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine", Athens

"Metaxa's Anticancer Hospital of Piraeus,1st Dep of Medical Oncology", Athens

401 Military Hospital, Medical Oncology Unit, Athens

Air Forces Military Hospital, Dep of Medical Oncology, Athens

"IASO General Hospital of Athens, 1st Dep of Medical Oncology", Athens

Sismanogleio General Hospital, 1st, 2nd Dep of Pulmonary Diseases, Athens

"Sotiria General Hospital, 1st, 3rd, 8th Dep of Pulmonary Diseases", Athens

"Theagenion Anticancer Hospital of Thessaloniki", Thessaloniki